logo

Ocular Therapeutix Inc. (OCUL)



Trade OCUL now with
  Date
  Headline
12/3/2018 7:16:11 AM Ocular Therapeutix: FDA Approve DEXTENZA 0.4mg For Treatment Of Ocular Pain Following Ophthalmic Surgery
10/19/2018 7:58:18 AM Ocular Therapeutix Receives FDA Warning Letter Related To ReSure Sealant
7/19/2018 8:08:28 AM Ocular Therapeutix Announces FDA Acceptance Of NDA Resubmission For DEXTENZA
6/29/2018 8:03:56 AM Ocular Therapeutix Announces NDA Resubmission Of DEXTENZA
5/3/2018 8:43:06 AM Ocular Announces Treatment Of 1st Patient In Phase 1 Trial Of OTX-TIC For Treatment Of Glaucoma And Ocular Hypertension
3/8/2018 7:33:10 AM Ocular Therapeutix Q4 Loss/shr $0.44 Vs. Loss/shr $0.52 Prior Year
1/25/2018 9:11:01 AM Ocular Therapeutix Prices Underwritten Public Offering Of 6.50 Mln Shares At $5.00/shr For Gross Proceeds Of $32.5 Mln
1/24/2018 4:02:28 PM Ocular Therapeutix Announces Proposed Public Offering Of Common Stock
10/14/2016 8:18:53 AM RBC Capital Markets Is Raising Ocular Therapeutix Inc. (OCUL) 2018 Estimate To -3.42 From -3.49
10/14/2016 8:18:35 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 2017 Estimate To -3.53 From -2.98
8/11/2015 10:46:17 AM RBC Capital Markets Is Cutting Ocular Therapeutix Inc. (OCUL) 4Q15 Estimate To -0.40 From -0.39
8/11/2015 10:46:00 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 3Q15 Estimate To -0.38 From -0.37
8/11/2015 10:45:27 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 4Q15 Rev. Estimate To 0.6 M From 0.9 M
8/11/2015 10:45:13 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 3Q15 Rev. Estimate To 0.4 M From 0.6 M
8/11/2015 10:44:41 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 2016 Estimate To -2.67 From -2.65
8/11/2015 10:44:25 AM RBC Capital Markets Is Cutting Ocular Therapeutix Inc. (OCUL) 2015 Estimate To -1.59 From -1.50
8/11/2015 10:43:57 AM RBC Capital Markets Is Lowering Ocular Therapeutix Inc. (OCUL) 2016 Rev. Estimate To 3.6 M From 4.3 M